Securities code: 688056 securities abbreviation: Beijing Labtech Instruments Co.Ltd(688056) Announcement No.: 2022-006 Beijing Labtech Instruments Co.Ltd(688056)
Announcement of 2021 annual performance express
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
The main financial data of 2021 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm. The specific data shall be subject to the data disclosed in the 2021 annual report of Beijing Labtech Instruments Co.Ltd(688056) (hereinafter referred to as “the company”), and investors are reminded of investment risks.
1、 Main financial data and indicators in 2021
Unit: RMB
Increase and decrease of the project in the same period of last year in the reporting period
（％）
Total operating income 369402039.57 348604853.01 5.97
Operating profit 76780050.67 69226450.46 10.91
Total profit 81775013.94 76413893.80 7.02
Net profit attributable to the owner of the parent company 70198253.79 65211001.34 7.65 profit
Net profit attributable to the owner of the parent company after deducting 63778322.45 58333075.18 9.33 non recurring profits and losses
Basic earnings per share (yuan): 1.05 1.17 -10.26
The weighted average return on net assets was 9.20% and 13.98%, down 4.78 percentage points
Increase and decrease at the end of the reporting period
（％）
Total assets 893461853.83 852373343.14 4.82
Owner’s equity attributable to the parent company 787217654.67 740055405.51 6.37
Share capital 67000000.00 67000000.00 0.00
Net assets of 11.75, 11.05 and 6.33 per share attributable to the owner of the parent company (yuan)
Note: 1 The beginning amount of this report is the same as the end amount of the previous year legally disclosed.
2. The above financial data and indicators are filled in based on the consolidated statement data, but have not been audited. The final data are subject to the data disclosed in the company’s 2021 annual report.
2、 Description of operating performance and financial status
(I) operating conditions, financial conditions and main factors affecting operating performance during the reporting period
During the reporting period, the company achieved an operating income of 369402039.57 yuan, a year-on-year increase of 5.97%; The operating profit was 76780050.67 yuan, a year-on-year increase of 10.91%; The total profit was 81775013.94 yuan, a year-on-year increase of 7.02%; The net profit attributable to the owners of the parent company was 70198253.79 yuan, an increase of 7.65% year-on-year; The net profit attributable to the owner of the parent company after deducting non recurring profits and losses was 63778322.45 yuan, a year-on-year increase of 9.33%.
At the end of the reporting period, the company was in good financial condition, with total assets of 893461853.83 yuan, an increase of 4.82% over the beginning of the period; The owner’s equity attributable to the parent company was 787217654.67 yuan, an increase of 6.37% over the beginning of the period.
In 2021, the company’s operating revenue increased by 5.97% year-on-year and its operating profit increased by 10.91% year-on-year. Covid-19 epidemic still occurred from time to time during the reporting period. The company’s business was affected to some extent. Although the company’s operating revenue and operating profit increased, the range was not high. Since its launch, the company’s new product inductively coupled plasma mass spectrometer (ICP-MS) in 2021 has been widely concerned by the market and investors. This new product began marketing in the fourth quarter of 2021 and obtained corresponding orders or cooperation agreements in semiconductor, medical and traditional fields. However, the launch time is still short and has not made significant contribution to the performance in 2021.
In 2021, the company’s net profit attributable to the owners of the parent company increased by 7.65% over the same period last year, and the net profit attributable to the owners of the parent company after deducting non recurring profits and losses finally increased by 9.33% over the same period last year. As the company implemented the equity incentive plan in 2021, the amount of share based payment expenses included in the reporting period was 3.346 million yuan. If the impact of the amount of share based payment after tax is deducted, the net profit after deducting non recurring profits and losses attributable to the owner of the parent company was 66.5699 million yuan, an increase of 14.12% compared with the same period last year.
3、 Risk tips
The main financial data of 2021 contained in this announcement is preliminary accounting data, which has not been audited by an accounting firm. The relevant indicators may be different from the data disclosed in the company’s 2021 annual report. The specific data shall be subject to the data disclosed in the company’s 2021 annual report, and investors are reminded of investment risks.
It is hereby announced.
Beijing Labtech Instruments Co.Ltd(688056) board of directors February 25, 2022
